Ahammune Biosciences develops proprietary small molecules that target deregulated cellular pathways in vitiligo, a chronic skin disease characterized by the loss of pigment-producing melanocytes. By restoring these pathways to their homeostatic state, the company aims to provide lasting relief with minimal side effects for individuals affected by this condition.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Vitiligo is a chronic skin condition affecting 1-2% of the global population, characterized by the loss of pigment-producing melanocytes, resulting in depigmentation and often causing significant psychological distress. Current treatments offer limited efficacy and do not address the underlying cellular dysregulation that leads to recurrent episodes of melanocyte destruction.
Solution
Ahammune Biosciences is developing targeted small molecule therapeutics designed to restore deregulated cellular pathways to their homeostatic state in individuals with vitiligo. By addressing the fundamental mechanisms that disrupt skin health, Ahammune's approach aims to provide lasting relief and minimize side effects. The company's proprietary molecules target the causal mechanisms leading to the breakdown of cellular functions, offering the potential for permanent remission of vitiligo symptoms. This therapeutic strategy focuses on re-establishing the complex structural and functional interaction networks within skin cells, promoting long-term skin health.
Target Audience
The primary target audience includes individuals affected by vitiligo, as well as dermatologists and other healthcare professionals specializing in skin disorders.
Features
- Proprietary small molecules designed to target specific deregulated cellular pathways in vitiligo.
- Focus on restoring skin homeostasis by modulating key cellular functions.
- Potential for permanent relief from vitiligo symptoms with minimal side effects.
- Designed to address the underlying causes of melanocyte destruction.